Achievement of target low-density lipoprotein ( LDL ) levels for secondary prevention is endorsed in Canadian guidelines but has been de-emphasized in the @ American College of Cardiology/American Heart Association coronary artery disease ( CAD ) guidelines in favor of initiation of statins or triple therapy ( antiplatelet agent , angiotensin converting enzyme inhibitor/angiotensin II receptor blocker , and statins ) .